Alnylam Pharmaceuticals, Inc. (ALNY) has a consensus analyst rating of Buy, based on 52 analysts covering the stock. Of those, 39 recommend buying, 12 recommend holding, and 1 recommend selling.
The analyst consensus price target for ALNY is $460.50, representing a +35.7% upside from the current price of $339.41. Price targets range from a low of $351.00 to a high of $549.00.
